BDX vs TMDX
BDX: BD is a leading global medical technology company providing essential medical devices, diagnostic systems, and laboratory solutions to healthcare providers and researchers worldwide. TMDX: TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
Side-by-side fundamentals
| Metric | BDX | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.16 | $71.20 | |
| Market cap as of 2026-07-23 | $42.2B | $2.5B | |
| P/E as of 2026-07-23 | 37.10 | 14.43 | TMDX lower |
| PEG as of 2026-07-23 | -20.92 | 0.08 | BDX lower |
| Net margin as of 2026-07-23 | +5.3% | +27.0% | TMDX higher |
| Gross margin as of 2026-07-23 | +47.0% | +59.1% | TMDX higher |
| Operating margin as of 2026-07-23 | +10.2% | +14.8% | TMDX higher |
| ROE as of 2026-07-23 | +4.5% | +41.9% | TMDX higher |
| ROA as of 2026-07-23 | +2.1% | +15.8% | TMDX higher |
| Debt / equity as of 2026-07-23 | 0.72 | 1.73 | BDX lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.4% | +30.2% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +86.4% | TMDX higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 0 | BDX higher |
| Beta as of 2026-07-23 | 0.21 | 1.94 | |
| 1-year return as of 2026-07-22 close | +7.5% | -32.6% | BDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.